Analysts’ Weekly Ratings Updates for Neurocrine Biosciences (NBIX)

Several analysts have recently updated their ratings and price targets for Neurocrine Biosciences (NASDAQ: NBIX):

  • 11/8/2019 – Neurocrine Biosciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/7/2019 – Neurocrine Biosciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $115.00 price target on the stock. According to Zacks, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company’s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. “
  • 11/5/2019 – Neurocrine Biosciences had its price target raised by analysts at Canaccord Genuity from $120.00 to $122.00. They now have a “buy” rating on the stock.
  • 11/5/2019 – Neurocrine Biosciences had its price target raised by analysts at Piper Jaffray Companies from $111.00 to $116.00.
  • 10/25/2019 – Neurocrine Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company’s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. “
  • 10/3/2019 – Neurocrine Biosciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $100.00 price target on the stock. According to Zacks, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company’s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. “
  • 10/1/2019 – Neurocrine Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company’s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. “

Shares of NASDAQ NBIX opened at $111.40 on Wednesday. Neurocrine Biosciences, Inc. has a 1-year low of $64.72 and a 1-year high of $113.12. The company has a market cap of $10.20 billion, a PE ratio of 506.36, a P/E/G ratio of 5.61 and a beta of 1.20. The company has a current ratio of 7.08, a quick ratio of 6.99 and a debt-to-equity ratio of 0.83. The company has a 50-day moving average of $96.21 and a two-hundred day moving average of $89.95.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Monday, November 4th. The company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.63 by ($0.07). Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The company had revenue of $222.09 million during the quarter, compared to the consensus estimate of $211.31 million. During the same period in the prior year, the firm posted $0.52 earnings per share. The company’s revenue was up 46.3% on a year-over-year basis. As a group, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 0.82 earnings per share for the current year.

In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 10,188 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $100.34, for a total value of $1,022,263.92. Following the completion of the transaction, the insider now directly owns 118,596 shares of the company’s stock, valued at $11,899,922.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Julie Cooke sold 987 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $88.56, for a total transaction of $87,408.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,795 shares of company stock valued at $3,681,988. Insiders own 4.30% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale raised its stake in shares of Neurocrine Biosciences by 48.7% in the second quarter. DekaBank Deutsche Girozentrale now owns 107,211 shares of the company’s stock worth $8,834,000 after acquiring an additional 35,131 shares during the last quarter. Holocene Advisors LP acquired a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $14,828,000. Rockefeller Capital Management L.P. grew its position in shares of Neurocrine Biosciences by 62.1% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 364,771 shares of the company’s stock worth $30,798,000 after buying an additional 139,794 shares during the period. NEXT Financial Group Inc grew its position in shares of Neurocrine Biosciences by 89.8% during the 2nd quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock worth $47,000 after buying an additional 265 shares during the period. Finally, GAM Holding AG grew its position in shares of Neurocrine Biosciences by 10.1% during the 2nd quarter. GAM Holding AG now owns 88,507 shares of the company’s stock worth $7,473,000 after buying an additional 8,100 shares during the period. 95.08% of the stock is owned by institutional investors.

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Featured Article: How is net asset value different from market price?

Receive News & Ratings for Neurocrine Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.